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Metropolitan area (population = 750,000) are treated. The following vari-
ables were collected from extensive medical records review: demographic 
information, detailed hematological information, medication and other 
active medical diagnoses that could have contributed to the neutropenia, 
clozapine regimen and use of GCS-F and lithium.
Results: The mean age at clozapine introduction was 35,9 yrs (range 
16–56). The mean observation period following the index neutropenia 
lasted 7.2 years (range 4 months -19,4). The mean delay between the index 
neutropenia and the re-challenge was 2.4  months. Five out of  these 22 
patients experienced additional neutropenias, and 3 of  these 5 patients ex-
perienced more than one additional neutropenias, one undergoing a total 
of  11 neutropenias. At the end of  the observation period, 17/22 patients 
were still on Clozapine; among the five patients in whom clozapine was 
stopped, three had died, one from a paralytic ileus that was deemed clo-
zapine-related, and 2 from non-clozapine related causes. One stopped 
Clozapine for a non-hematological side-effect, and only one stopped due 
to neutropenia, i.e., after an eleventh neutropenia despite concomitant 
GCS-F use.
Discussion: This study adds to available evidence that a clozapine re-
challenge or continuation following a neutropenia can be reasonably 
considered once potential risks and benefits have been carefully analyzed 
and then discussed with the patient and his/her family in order to make 
a shared decision. Furthermore, the present results raise the possibility 
that continuing clozapine with stringent hematological monitoring may 
be considered in some cases of  neutropenia that do not reach the agranu-
locytosis threshold. These results also support that conclusion that condi-
tions other than hematological ones (e.g., severe constipation) should be 
closely monitored and rigorously addressed in order to ensure the safety 
of  Clozapine use.
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Background: New medications with novel targets are needed for schiz-
ophrenia. Several lines of evidence indicate that inflammatory processes 
including aberrant lymphocytic activity may be related to the pathophys-
iology of this illness. These data suggest that agents with anti-inflamma-
tory actions, including modulation of lymphocytes and their inflammatory 
substrates, may prove to be efficacious for schizophrenia. Fingolimod is a 
powerful anti-inflammatory agent that is used in the treatment of relapsing 
multiple sclerosis. It is a sphingosine-1-phosphate (S1P) receptor modulator 
that decreases circulating lymphocytes through sequestration in lymph tis-
sues. In addition, evidence suggest that it stimulates oligodendrocytes and 
may enhance white matter integrity. The purpose of this study was to assess 
the effects of fingolimod in schizophrenia.
Methods: Subjects with schizophrenia (N=40) were recruited through the 
Indiana University Psychotic Disorders Programs and randomized 1:1 
in a double-blind, eight-week clinical trial of fingolimod 0.5 mg/day and 
placebo. Circulating total lymphocytes were determined and effects were 
assessed on symptoms (PANSS), cognition (BACS), plasma cytokines, 
white matter integrity (DTI) and cortical connectivity (resting fMRI).
Results: Results revealed a significant decrease in lymphocytes in subjects 
taking fingolimod versus placebo (treatment x time; F = 61.2, p < 0.001). 
Fingolimod treated subjects had a mean maximal drop in lymphocytes 
from baseline of 79.2% with all fingolimod treated subjects experiencing 
decrements greater than 60%. There was a trend toward higher mean skel-
etal fractional anisotropy (FA) post-treatment in the fingolimod group. 
Within the fingolmiod group, there were significant or trend-level correla-
tions between FA increase and decrease in lymphocytes in the genu and 
body of the corpus collosum and the right superior longitudinal fasciculus. 
There were also significant group-by-visit interactions in connectivity of 
left prefrontal cortical (PFC) seeds with clusters in the cerebellum, driven 
by higher PFC-cerebellum connectivity following fingolimod treatment. 
There were no improvements (treatment x time) in PANSS total (F = 0.66, 
p= 0.52), any of the PANSS subscales, or BACS composite score (F = 0.54, 
p = 0.44). Serious side effects were not observed, and a full safety report 
will be provided.
Discussion: Fingolimod produced a strong anti-inflammatory response 
with substantial reductions in circulating lymphocytes in all treated sub-
jects. Brain effects were observed. However, this response was not accom-
panied by improvements in symptoms or cognition. These data suggest that 
fingolimod’s target of S1P modulation and robust anti-inflammatory war-
rant further investigation in schizophrenia.
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Background: Low bone mineral density (BMD) may constitute an underes-
timated comorbidity in schizophrenia patients undergoing long-term anti-
psychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are 
antidiabetic drugs, which may also affect bone turnover.
The current study comprises planned secondary analyses of the ‘TAO 
study’: Treatment of antipsychotic-associated obesity with a GLP-1 recep-
tor agonist. The TAO study was an investigator-initiated, double-blind, 
randomized, placebo-controlled trial, investigating the effects of three 
months treatment with the GLP-1 receptor agonist exenatide 2 mg once-
weekly in chronic obese, antipsychotic-treated patients with schizophrenia 
spectrum disorder.
Methods: First, we compared baseline bone turnover markers (BTMs) of 45 
chronic, obese, antipsychotic-treated patients with the Danish Health2006 
study cohort as reference population, and we calculated bone mineral den-
sity (BMD) T- and Z-scores.
Second, investigated effects of three months of GLP-1 receptor agonist 
exenatide 2  mg once-weekly (n=23), or placebo (n=22) on BTMs and 
BMD in these patients. Data were initially analyzed without covariates by 
two-way repeated measures ANOVA. All analyses were repeated with mean 
prolactin level as a covariate to evaluate the potential effect of prolactin.
Results: In women (n=24), all baseline BTM measurements of procollagen 
type I N-terminal propeptide (PINP) and C-terminal cross-linking telopep-
tide of type I collagen (CTX) were within reference values. In men (n=21), 
5% displayed lower PINP and 14% displayed lower CTX. One patient dis-
played BMD Z-score <-2, and 23% of patients (17% of women and 29% 
